Ionis Pharmaceuticals, Inc. research snapshot
IONS AI stock analysis currently reads Ionis Pharmaceuticals, Inc. as a commercial-stage RNA medicine company with an approved TRYNGOLZA severe hypertriglyceridemia indication, growing independent product sales, partner royalties, and several late-stage catalysts, but also negative earnings, cash burn, and a fresh WAINUA ATTR-CM trial failure. At the August 3, 2026 data cutoff, IONS last closed at $51.77 on July 31, implying a calculated market capitalization of about $8.60 billion using 166.18 million shares. Q2 2026 revenue of $268 million beat the consensus near $190 million, and GAAP EPS of -$0.69 beat the consensus of -$0.88, but the stock still closed the week lower as the market weighed the sHTG launch, the eplontersen setback, and continued losses. This IONS AI stock analysis uses scenario ranges, technical levels, and source-backed facts for information only. It is not investment advice.
Current price
$51.77
Market cap
$8.60 billion calculated from 166.18 million shares
AI score
52 / 100
Rating
RNA medicines platform with Q2 2026 revenue beat, TRYNGOLZA sHTG approval, high event risk, and negative cash flow
Trend status
Short-term bearish after the CARDIO-TTRansform miss and a continued drift from the July gap; long-term platform trend unconfirmed
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Ionis discovers and develops RNA-targeted medicines, with TRYNGOLZA and DAWNZERA sales, SPINRAZA and WAINUA royalties, and a partner-rich late-stage pipeline. | High |
| Moat | ASO chemistry, delivery know-how, disease biology, clinical experience, intellectual property, and a partner network form a real platform moat, but each product still needs clinical and commercial validation. | Medium-high |
| Management | Brett Monia's team is moving from partner-dependent royalties toward independent launches and a 2028 cash-flow breakeven goal; execution after the July trial miss and the slow TRYNGOLZA revenue ramp is the key test, with CSO Frank Bennett's retirement adding a key-person transition. | Medium |
| Financial trend | FY2025 revenue rose 34% to $943.7 million and net loss narrowed to $381.4 million; Q2 2026 revenue was $268 million with EPS of -$0.69, but TTM revenue fell to $874.1 million and TTM net loss widened to about -$565 million. | High |
| Valuation | At $51.77, IONS trades at about 9.84x TTM revenue and 9.11x FY2025 revenue, with negative EPS and negative free cash flow, so cheapness cannot be established using PE or FCF yield. | High |
| Technical trend | Daily technicals stayed bearish through July 31; RSI 26.31 is approaching oversold while price sits below the 10-day, 20-day, 50-day, and 200-day simple moving averages. | High |
| Risk level | Risk is high because of the WAINUA ATTR-CM failure, negative free cash flow, partner and revenue concentration, short interest near 12% of shares out, regulatory outcomes, and launch execution. | High |
| AI confidence | Confidence is high for reported facts and calculations, but lower for price outcomes because trial and regulatory events can overwhelm technical or valuation models. | High data confidence |
| Investment certainty | Ionis has platform, approval, and product evidence, but the current thesis requires proof of independent commercial growth and a credible path to cash-flow breakeven after a major clinical setback and a lower share price. | Low-medium |
IONS AI stock forecast
The IONS AI stock forecast is a medium-term scenario framework, not a price promise. Ionis is loss-making, so the audited three-scenario EPS command produces negative target prices when applied to TTM GAAP EPS of -$3.46; that output is not decision-useful. The ranges below are conditional market-re-rating bands anchored to $51.77, the July 31 close, plus current launch guidance, cash-burn risk, and pipeline outcomes, not a fabricated intrinsic-value estimate.
$80 to $110
More likely if TRYNGOLZA sHTG adoption scales quickly after the June 24 approval, DAWNZERA keeps gaining HAE prophylaxis share, zilganersen wins approval at the September 22 PDUFA, bepirovirsen wins approval at the October 26 PDUFA, pelacarsen or obudanersen data stay positive, and the full CARDIO-TTRansform data set preserves a viable eplontersen franchise.
$55 to $80
More likely if TRYNGOLZA and DAWNZERA ramp toward the 2026 product guidance of $100 million to $110 million and $110 million to $120 million, SPINRAZA and WAINUA royalties remain durable, and part of the pipeline progresses, while WAINUA loses its ATTR-CM expansion option and Ionis remains loss-making through the next investment cycle.
$30 to $50
More likely if TRYNGOLZA sHTG launch, pricing, or reimbursement disappoints after the April WAC cut, zilganersen, bepirovirsen, pelacarsen, or obudanersen slip or fail, WAINUA royalties weaken after the trial miss, and cash burn requires further financing or dilution with the price below the July low near $50.
IONS AI technical analysis
IONS AI technical analysis is bearish and drifting lower as of the July 31, 2026 close. The stock closed at $51.77 after a multi-week slide from the July 9 event gap, with RSI near 26.31 and price below the computed 10-day SMA of $54.31, the 20-day SMA of $59.75, the 50-day SMA of $69.45, and the 200-day SMA of $75.17. The July 9 and July 10 selloff followed the official WAINUA trial update, and the drift since then means an oversold bounce would not by itself confirm a trend reversal.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $51.77 | StockAnalysis historical close for July 31, 2026, the latest completed trading session before the August 3 cutoff. |
| Immediate support | $50.01 to $51.28 | The July 22 low was $50.01 and the July 31 low was $51.28. A decisive close below this zone would leave the post-event breakdown without a tested short-term floor and open the path toward the 52-week low. |
| First resistance | $54.04 to $55.36 | The July 29 close was $54.04 and the July 29 high was $55.36. This zone is the first reference for a stabilization attempt. |
| Next resistance | $57.48 to $58.25 | The July 23 high was $57.48 and the July 10 close was $58.25. A reclaim would improve short-term structure but would not repair the clinical thesis by itself. |
| Moving averages | 10-day $54.31; 20-day $59.75; 50-day $69.45; 200-day $75.17 | 10-day and 20-day values are computed from StockAnalysis closes through July 31, 2026; 50-day and 200-day values are from the StockAnalysis statistics snapshot. Price is below every listed average. |
| Momentum | RSI(14) 26.31 | The RSI reading is low and approaching oversold, but it has not produced a confirmed reversal signal while price keeps printing lower closes. |
| Volume | 2.55 million shares on July 31; 20-day average 4.66 million | Volume has normalized below the 20-day average after the July 9 and July 10 event spike, indicating the current drift is happening on lighter participation. |
| Volatility | Beta 0.37; 52-week range $40.03 to $86.74 | The moderate beta and wide 52-week range indicate that position sizing and gap risk matter more than a single indicator for a clinical-event biotech stock. |
| Short interest | 20.04 million shares, about 12.06% of shares out, 5.18 days to cover | Short interest stayed elevated through late July, which can add to both downside pressure and squeeze risk on any positive catalyst. |
| Invalidation | Close below $50.01 weakens the setup; stabilization requires $54.04, then $57.48 to $58.25 | A close below the July 22 low weakens the oversold-bounce setup. Reclaiming the first resistance zones would be required before considering a technical recovery. |
IONS AI trading strategy
The IONS AI trading strategy is a rules-based framework for a clinical-event biotechnology stock, not personal advice. It should be used with live quotes, position sizing, SEC filings, the clinical calendar, regulatory updates, and explicit risk rules.
Wait for IONS to close back above $54.04 and then challenge $57.48 to $58.25 with confirming volume and no new negative clinical, regulatory, or product news. A later reclaim of the 20-day average near $59.75 would improve short-term confirmation, but the 50-day and 200-day averages remain well overhead.
A close below $50.01 invalidates the immediate recovery setup. Treat a gap below that level as event risk rather than as a routine pullback.
An RSI near 26.31 can support a tactical bounce toward $54.04 to $58.25 if the market receives no new negative information. Compare any bounce with volume, the ESC eplontersen presentation, TRYNGOLZA demand, zilganersen and bepirovirsen PDUFA news, and the next earnings release.
Do not treat oversold conditions as proof of a bottom. A new clinical or regulatory problem can push through support before a mean-reversion signal completes.
Track TRYNGOLZA severe hypertriglyceridemia sales and net price, DAWNZERA sales, WAINUA ATTRv-PN royalties and global sales, SPINRAZA royalties, 2026 revenue guidance of $875 million to $900 million, cash above $1.6 billion, the 2028 cash-flow breakeven goal, short interest, and each major readout or PDUFA date.
Reduce confidence if guidance falls, TRYNGOLZA or DAWNZERA miss product guidance, cash drops below the stated floor, financing or dilution increases, or pipeline outcomes fail to replace the lost ATTR-CM expansion opportunity.
Investment research summary
Ionis turns RNA target selection, antisense chemistry, delivery know-how, clinical evidence, regulatory work, and commercial partnerships into medicines and royalties. Q2 2026 commercial revenue was $119 million and research and development revenue was $149 million, showing both the product engine and the lumpy deal engine.
The moat is strongest in accumulated ASO chemistry, delivery, disease biology, clinical development, intellectual property, regulatory experience, and partner access. It is not an automatic moat around every asset: competing modalities, safety, dosing, reimbursement, and clinical endpoints can still decide product success, as the eplontersen ATTR-CM result showed.
The thesis can fail through a second pipeline setback, weak TRYNGOLZA or DAWNZERA adoption after the April price cut, lower pricing, slower royalties, partner reprioritization, continued negative cash flow, or new financing and dilution. The July 2026 WAINUA ATTR-CM miss shows why a broad pipeline does not remove binary risk, and the July share drift shows how long the market can stay skeptical.
CEO Brett Monia and CFO Elizabeth Hougen are trying to shift Ionis toward independent launches while retaining large pharmaceutical partners. TRYNGOLZA sHTG approval, the Recordati license for zilganersen outside the U.S., the 2028 cash-flow breakeven goal, and the maintained 2026 guidance show active capital and commercial planning, but CSO Frank Bennett retires in February 2027 and sustained execution is still unproven.
RNA medicines and gene silencing are part of a long-term shift toward therapies that act on disease biology upstream of proteins. Ionis has commercial proof through SPINRAZA, TRYNGOLZA, DAWNZERA, and newer launches, but the industry remains exposed to competing modalities, payer pressure, safety, manufacturing, regulatory standards, and clinical endpoint design.
At a calculated market capitalization of about $8.60 billion, IONS traded near 9.84x TTM revenue and 9.11x FY2025 revenue while GAAP earnings and free cash flow were negative. The current margin of safety therefore depends on future launch revenue, partner royalties, pipeline approvals, and a credible path to cash-flow breakeven rather than on current earnings power.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IONS latest completed-session price | $51.77 at the July 31, 2026 close | StockAnalysis historical data | August 3, 2026 |
| Market capitalization | $8.60 billion, calculated as $51.77 x 166.18 million shares; market cap verification variance 0.04% | StockAnalysis share snapshot and financial_rigor.py | August 3, 2026 |
| Shares outstanding reference | 166.18 million current share snapshot; FY2025 weighted-average shares were 160.01 million and year-end common shares were 163.305 million | StockAnalysis and Ionis 2025 Form 10-K | August 3, 2026 |
| FY2025 revenue trend | $943.711 million in 2025, versus $705.138 million in 2024 and $787.647 million in 2023 | Ionis 2025 Form 10-K and StockAnalysis | August 3, 2026 |
| TTM revenue and net loss trend | TTM revenue through June 30, 2026 was $874.09 million, down 7.4% year over year, with a TTM net loss of about -$565 million and TTM EPS of -$3.46 | StockAnalysis statistics and income statement | August 3, 2026 |
| Q2 2026 financial results | $268 million total revenue versus consensus near $190 million, $119 million commercial revenue, $149 million research and development revenue, and GAAP EPS of -$0.69 versus consensus of -$0.88 | Ionis Q2 2026 earnings release and earnings call transcript | August 3, 2026 |
| H1 2026 product revenue | H1 2026 revenue was $514 million, up 56% excluding the prior-year $280 million Ono payment; commercial revenue was $226 million; TRYNGOLZA product sales were $32 million ($5 million in Q2 after the April 1 WAC reduction) and DAWNZERA product sales were $42 million | Ionis Q2 2026 earnings call transcript | August 3, 2026 |
| Cash and short-term investments | $2.1 billion at June 30, 2026; $2.677 billion at December 31, 2025 before the $633 million 2026 convertible-note maturity payment | Ionis Q2 2026 earnings call and 2025 Form 10-K | August 3, 2026 |
| 2026 financial guidance | $875 million to $900 million total revenue, $425 million to $475 million non-GAAP operating loss, and more than $1.6 billion cash and short-term investments; TRYNGOLZA sales $100 million to $110 million and DAWNZERA sales $110 million to $120 million | Ionis Q2 2026 earnings call | August 3, 2026 |
| Commercial and pipeline catalysts | TRYNGOLZA was approved for severe hypertriglyceridemia on June 24, 2026; zilganersen has a September 22, 2026 PDUFA target; bepirovirsen has an October 26, 2026 PDUFA target; pelacarsen HORIZON data are expected in the second half of 2026; obudanersen REVEAL enrollment completed July 6, 2026 | FDA, Ionis press releases, and Ionis Q2 2026 earnings call | August 3, 2026 |
| WAINUA CARDIO-TTRansform result | Phase 3 did not meet the primary composite endpoint; eplontersen showed substantial TTR reductions and nominally significant monotherapy-subgroup results, with detailed data planned for ESC in August 2026 | AstraZeneca and Ionis trial update and Q2 2026 earnings call | August 3, 2026 |
| Analyst consensus and price targets | 23 analysts rate IONS Buy with an average 12-month price target of $89.14; recent changes include BofA to $93, H.C. Wainwright to $115, and Goldman Sachs to $69 | StockAnalysis analyst forecast | August 3, 2026 |
| TTM free cash flow and valuation check | Approximate TTM FCF of -$560.84 million; PE and P/FCF are negative, while price to TTM revenue per share is 9.84x and price to FY2025 revenue per weighted-average share is about 9.11x | StockAnalysis statistics and financial_rigor.py | August 3, 2026 |
| Technical snapshot | RSI 26.31; SMA50 $69.45; SMA200 $75.17; computed SMA10 $54.31 and SMA20 $59.75; short interest 20.04 million shares or about 12.06% of shares out | StockAnalysis statistics and computed from historical closes | August 3, 2026 |
| Event-driven price and volume move | Close moved from $84.46 on July 8 to $64.27 on July 9 and $58.25 on July 10, then drifted to $51.77 by July 31; volume was 20.45 million and 11.44 million shares on July 9 and July 10 respectively | StockAnalysis historical data | August 3, 2026 |
This IONS AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are conditional scenarios based on available data as of August 3, 2026 and can be wrong if financial results, clinical data, regulation, competition, financing, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
